English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Furin is a serine protease that takes part in the processing and activationof the host cell pre-proteins. The enzyme also plays an important role in theactivation of several viruses like the newly emerging SARS-CoV-2 virus thatcauses COVID-19 disease with a high rate of virulence and mortality. Unlikeviral enzymes, furin owns a constant sequence and active site characteristicsand seems to be a better target for drug design for COVID-19 treatment.Considering furin active site as receptor and some approved drugs fromdifferent classes including antiviral, antibiotics, and anti protozoa/antiparasites with suspected beneficial effects on COVID-19, as ligands we havecarried out docking experiments in HEX software to pickup those capable to bindfurin active site with high affinity and suggest them as probable candidatesfor clinical trials assessments. Our docking experiments show that saquinavir,nelfinavir, and atazanavir with cumulative inhibitory effects of 2.52, 2.16,and 2.13 respectively seem to be the best candidates for furin inhibition evenin severe cases of COVID-19 as adjuvant therapy, while clarithromycin,niclosamide, and erythromycin with cumulative inhibitory indices of 1.97, 1.90,and 1.84 respectively with lower side effects than antiviral drugs could besuggested as prophylaxes for the first stage of COVID-19 as a promising treat.

New Candidates for Furin Inhibition as Probable Treat for COVID-19: Docking Output